Difference between revisions of "MSK Biomarker Ctte"

From QIBA Wiki
Jump to: navigation, search
(Working Documents)
(Meetings)
 
Line 10: Line 10:
  
 
'''Approved call summaries:'''
 
'''Approved call summaries:'''
 +
*[[Media:2019_10-22_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 22, 2019]]
 
*[[Media:2019_09-24_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 24, 2019]]
 
*[[Media:2019_09-24_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 24, 2019]]
 
*[[Media:2019_06-25_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|June 25, 2019]]
 
*[[Media:2019_06-25_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|June 25, 2019]]
*[[Media:2019_05-28_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|May 28, 2019]]
 
  
 
'''''[[MSK Biomarker Committee Call Summaries Archive]]'''''
 
'''''[[MSK Biomarker Committee Call Summaries Archive]]'''''

Latest revision as of 15:53, 24 March 2020

Co-chairs: Thomas M. Link, MD, PhD; Xiaojuan Li, PhD
RSNA Staff Support: Susan Stanfa

The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.


Meetings

Approved call summaries:

MSK Biomarker Committee Call Summaries Archive

Working Documents

  • QIBA MSK Profile 2020-01-28: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease

Statistical Reference Documents

Workflow Documents

Reference Materials